Highbridge Capital Management buys $48,104,233 stake in Hologic (HOLX)

Hologic (HOLX) : Highbridge Capital Management scooped up 805,889 additional shares in Hologic during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 1,309,315 shares of Hologic which is valued at $48,104,233.Hologic makes up approximately 1.27% of Highbridge Capital Management’s portfolio.

Other Hedge Funds, Including , Gsa Capital Partners Llp reduced its stake in HOLX by selling 22,334 shares or 59.26% in the most recent quarter. The Hedge Fund company now holds 15,356 shares of HOLX which is valued at $559,726. Hologic makes up approx 0.03% of Gsa Capital Partners Llp’s portfolio. Checchi Capital Advisers sold out all of its stake in HOLX during the most recent quarter. The investment firm sold 2,281 shares of HOLX which is valued $85,766.Brown Advisory Securities reduced its stake in HOLX by selling 137 shares or 1.67% in the most recent quarter. The Hedge Fund company now holds 8,089 shares of HOLX which is valued at $304,146. Hologic makes up approx 0.09% of Brown Advisory Securities’s portfolio.Mutual Of America Capital Management boosted its stake in HOLX in the latest quarter, The investment management firm added 6,269 additional shares and now holds a total of 34,281 shares of Hologic which is valued at $1,212,519. Hologic makes up approx 0.03% of Mutual Of America Capital Management’s portfolio. Spot Trading L.l.c sold out all of its stake in HOLX during the most recent quarter. The investment firm sold 85 shares of HOLX which is valued $3,031.

Hologic closed down -0.21 points or -0.54% at $38.37 with 19,16,246 shares getting traded on Monday. Post opening the session at $38.52, the shares hit an intraday low of $38 and an intraday high of $38.69 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Hologic reported $0.52 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Nov 2, 2016. Analyst had a consensus of $0.50. The company had revenue of $726.80 million for the quarter, compared to analysts expectations of $721.76 million. The company’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS.

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.